Skip to main content
Top
Published in: Journal of Cancer Survivorship 3/2010

01-09-2010

Fertility in patients treated for testicular cancer

Authors: Erika Matos, Breda Škrbinc, Branko Zakotnik

Published in: Journal of Cancer Survivorship | Issue 3/2010

Login to get access

Abstract

Introduction

Testicular cancer affects men mostly in their reproductive age with a cure rate over 90% and fertility is one of the main concerns of survivors. To further elucidate the question of fertility after treatment for testicular cancer, we performed a survey in patients treated in our institution.

Patients and methods

We sent a questionnaire to patients treated for testicular cancer at our institute from 1976 to 2002 (n = 490) of whom 297 (60.6%) responded. We considered the patients to have conserved fertility if they had children after treatment without assisted reproductive technologies.

Results

Before treatment 119/297 (40.1%) of patients and after treatment 150/297 (50.5%) of patients tried to have children (p = 0.019). Of 119 patients who tried to have children before treatment for testicular cancer 98 (82.4%) succeeded and 74/150 (49.3%) were successful after treatment (p < 0.001). After treatment patients had 1–3 (median 1) children. The median time to birth of first child from diagnosis was 12 years. The post-treatment fatherhood in patients treated with surgery only (orchidectomy +/− retroperitoneal lymphnode dissection-RPLND) was 59%, in those with additional radiotherapy 68%, and chemotherapy 50% (p = 0.233). Fertility rate in patients where a non nerve sparing RPLND was performed was only 37%, 62% in patients with nerve sapring RPLND, and 77% in patients where RPLND was not performed (p < 0.0001).

Conclusion

Fertility rate after treatment for testicular cancer is reduced. From our data, the most important treatment modality that influences fertility is non nerve sparing RPLND that should be avoided whenever possible in order improve the quality of life our patients.
Literature
1.
go back to reference Cancer incidence in Slovenia 1989, Ljubljana: Instutute of Oncology Ljubljnana, Cancer Registry of Republic of Slovenia, 1989. Cancer incidence in Slovenia 1989, Ljubljana: Instutute of Oncology Ljubljnana, Cancer Registry of Republic of Slovenia, 1989.
2.
go back to reference Cancer incidence in Slovenia 2004, Ljubljana: Instutute of Oncology Ljubljnana, Cancer Registry of Republic of Slovenia, 2004. Cancer incidence in Slovenia 2004, Ljubljana: Instutute of Oncology Ljubljnana, Cancer Registry of Republic of Slovenia, 2004.
3.
go back to reference Richiardi L, Pettersson A, Akre O. Genetic and environmental risk factors for testicular cancer. Int J Androl. 2007;30:230–40.CrossRefPubMed Richiardi L, Pettersson A, Akre O. Genetic and environmental risk factors for testicular cancer. Int J Androl. 2007;30:230–40.CrossRefPubMed
4.
go back to reference Huyghe E, Plante P, Thonneau PF. Testicular cancer variations in time and space in Europe. Eur Urol. 2007;51:621–8.CrossRefPubMed Huyghe E, Plante P, Thonneau PF. Testicular cancer variations in time and space in Europe. Eur Urol. 2007;51:621–8.CrossRefPubMed
6.
go back to reference Verdecchia A, Francisci S, Brenner H, et al. EUROCARE-4 Working Group. Lancet Oncol. 2007;8:784–96.CrossRefPubMed Verdecchia A, Francisci S, Brenner H, et al. EUROCARE-4 Working Group. Lancet Oncol. 2007;8:784–96.CrossRefPubMed
8.
go back to reference Fosså SD, Magelssen H. Fertility and reproduction after chemotherapy of adult cancer patients: malignant lymphoma and testicular cancer. Ann Oncol. 2004;15 Suppl 4:iv259–65.PubMed Fosså SD, Magelssen H. Fertility and reproduction after chemotherapy of adult cancer patients: malignant lymphoma and testicular cancer. Ann Oncol. 2004;15 Suppl 4:iv259–65.PubMed
9.
go back to reference Mitwally MF. Ferility preservation and minimizing reproductive damage in cancer survivors. Expert Rev Anticancer Ther. 2007;7:989–1001. Review.CrossRefPubMed Mitwally MF. Ferility preservation and minimizing reproductive damage in cancer survivors. Expert Rev Anticancer Ther. 2007;7:989–1001. Review.CrossRefPubMed
10.
go back to reference Byrne J, Mulinhill JJ, Myers MH, et al. Effects of treatment on fertility in long-term survivors of childhood or adolescent cancer. N Engl J Med. 1987;317:1315–21.CrossRefPubMed Byrne J, Mulinhill JJ, Myers MH, et al. Effects of treatment on fertility in long-term survivors of childhood or adolescent cancer. N Engl J Med. 1987;317:1315–21.CrossRefPubMed
11.
go back to reference Fosså SD, Kravdal O. Fertility in Norwegian testicular cancer patients. Br J Cancer. 2000;82:737–41.CrossRefPubMed Fosså SD, Kravdal O. Fertility in Norwegian testicular cancer patients. Br J Cancer. 2000;82:737–41.CrossRefPubMed
12.
go back to reference Fosså SD. Long-term sequelae after cancer therapy—survivorship after treatment for testicular cancer. Acta Oncol. 2004;43:134–41. Review.CrossRefPubMed Fosså SD. Long-term sequelae after cancer therapy—survivorship after treatment for testicular cancer. Acta Oncol. 2004;43:134–41. Review.CrossRefPubMed
13.
go back to reference Dubin L, Amelar RD. Etiologic factors in 1294 consecutive cases of male infertility. Fertil Steril. 1971;22:469–74.PubMed Dubin L, Amelar RD. Etiologic factors in 1294 consecutive cases of male infertility. Fertil Steril. 1971;22:469–74.PubMed
14.
go back to reference Douchez J, Droz JP, Desclaux B, et al. Quality of life in long-term survivors of nonseminatous germ cell testicular tumors. J Urol. 1993;149:498–501.PubMed Douchez J, Droz JP, Desclaux B, et al. Quality of life in long-term survivors of nonseminatous germ cell testicular tumors. J Urol. 1993;149:498–501.PubMed
15.
16.
go back to reference Narajan P, Lange PH, Fraley EE. Ejaculation and fertility after extended retroperitoneal lymph node dissection for testicular cancer. J Urol. 1982;127:685–8. Narajan P, Lange PH, Fraley EE. Ejaculation and fertility after extended retroperitoneal lymph node dissection for testicular cancer. J Urol. 1982;127:685–8.
17.
go back to reference Nijman JM, Jager S, Boer PW, Kremer J, et al. The treatment of ejaculation disorders after retroperitoneal lymph node dissection. Cancer. 1982;50:2967–71.CrossRefPubMed Nijman JM, Jager S, Boer PW, Kremer J, et al. The treatment of ejaculation disorders after retroperitoneal lymph node dissection. Cancer. 1982;50:2967–71.CrossRefPubMed
18.
go back to reference Sogani PC. Evolution of the management of stage I nonseminomatous germ-cell tumors of the testis. Urol Clin North Am. 1991;18:561–73.PubMed Sogani PC. Evolution of the management of stage I nonseminomatous germ-cell tumors of the testis. Urol Clin North Am. 1991;18:561–73.PubMed
19.
go back to reference Foster SD, McNulty A, Rubin LR, et al. The fertility of patients with clinical stage I testis cancer managed by nerve sparing retroperitoneal lymph node dissection. J Urol. 1994;152:1139–43.PubMed Foster SD, McNulty A, Rubin LR, et al. The fertility of patients with clinical stage I testis cancer managed by nerve sparing retroperitoneal lymph node dissection. J Urol. 1994;152:1139–43.PubMed
20.
go back to reference Gandini L, Sgrò P, Lombardo F, et al. Effect of chemo- or radiotherapy on sperm parameters of testicular cancer patients. Hum Reprod. 2006;21:2882–9.CrossRefPubMed Gandini L, Sgrò P, Lombardo F, et al. Effect of chemo- or radiotherapy on sperm parameters of testicular cancer patients. Hum Reprod. 2006;21:2882–9.CrossRefPubMed
21.
go back to reference Howell SJ, Shalet SM. Spermatogenesis after cancer treatment: Damage and recovery. J Natl Cancer Inst Monogr. 2005;34:12–7.CrossRefPubMed Howell SJ, Shalet SM. Spermatogenesis after cancer treatment: Damage and recovery. J Natl Cancer Inst Monogr. 2005;34:12–7.CrossRefPubMed
22.
go back to reference Pont J, Albrecht W. Fertility after chemotherapy for testicular germ cell cancer. Fertil Steril. 1997;68:1–5.CrossRefPubMed Pont J, Albrecht W. Fertility after chemotherapy for testicular germ cell cancer. Fertil Steril. 1997;68:1–5.CrossRefPubMed
23.
go back to reference Taksey J, Bissada NK, Chaudhary UB. Fertility after chemotherapy for testicular cancer. Arch Androl. 2003;49:389–95.CrossRefPubMed Taksey J, Bissada NK, Chaudhary UB. Fertility after chemotherapy for testicular cancer. Arch Androl. 2003;49:389–95.CrossRefPubMed
24.
go back to reference Halperin EC, Perez CA, Brady LW. Principles and practice of radiation oncology, 5th ed, Wolters Kluwer/Lippincott Williams&Wilkins 2008: 1513–1515. Halperin EC, Perez CA, Brady LW. Principles and practice of radiation oncology, 5th ed, Wolters Kluwer/Lippincott Williams&Wilkins 2008: 1513–1515.
25.
go back to reference Thonneau P, Marchand S, Tallec A, et al. Incidence and main causes of infertility in a resident population (1,850,000) of three French regions (1988–1989). Hum Reprod. 1991;6:811–6.PubMed Thonneau P, Marchand S, Tallec A, et al. Incidence and main causes of infertility in a resident population (1,850,000) of three French regions (1988–1989). Hum Reprod. 1991;6:811–6.PubMed
26.
go back to reference Baker JA, Buck GM, Vena JE, et al. Fertility patterns prior to testicular cancer diagnosis. Cancer Causes Control. 2005;16:295–9.CrossRefPubMed Baker JA, Buck GM, Vena JE, et al. Fertility patterns prior to testicular cancer diagnosis. Cancer Causes Control. 2005;16:295–9.CrossRefPubMed
28.
go back to reference Huddart RA, Norman A, Horwich A, et al. Fertility, gonadal and sexual function in survivors of testicular cancer. Br J Cancer. 2005;93:200–7.CrossRefPubMed Huddart RA, Norman A, Horwich A, et al. Fertility, gonadal and sexual function in survivors of testicular cancer. Br J Cancer. 2005;93:200–7.CrossRefPubMed
29.
go back to reference Brydøy M, Fosså SD, Olbjørn K, et al. Paternity following treatment for testicular cancer. J Natl Cancer Inst. 2005;97:1580–8.CrossRefPubMed Brydøy M, Fosså SD, Olbjørn K, et al. Paternity following treatment for testicular cancer. J Natl Cancer Inst. 2005;97:1580–8.CrossRefPubMed
30.
go back to reference Hartmann JT, Albrecht C, Schmoll HJ, et al. Long-term effects on sexual function and fertility after treatment of testicular cancer. Br J Cancer. 1999;80:801–7.CrossRefPubMed Hartmann JT, Albrecht C, Schmoll HJ, et al. Long-term effects on sexual function and fertility after treatment of testicular cancer. Br J Cancer. 1999;80:801–7.CrossRefPubMed
31.
go back to reference Cvancarova M, Samuelsen SO, Magelssen H, et al. Reproduction rates after cancer treatment: Experiences from the Norwegian Radium hospital. J Clin Oncol. 2009;27:334–43.CrossRefPubMed Cvancarova M, Samuelsen SO, Magelssen H, et al. Reproduction rates after cancer treatment: Experiences from the Norwegian Radium hospital. J Clin Oncol. 2009;27:334–43.CrossRefPubMed
32.
go back to reference Howell SJ, Shalet SM. Testicular function following chemotherapy. Hum Reprod Update. 2001; Jul–Aug 7: 363–369. Review. Howell SJ, Shalet SM. Testicular function following chemotherapy. Hum Reprod Update. 2001; Jul–Aug 7: 363–369. Review.
33.
go back to reference Colpi GM, Contalbi GF, Nerva F, et al. Testicular function following chemo-radiotherapy. Eur J Obstet Gynecol Reprod Biol. 2004;113 Suppl 1:S2–6.CrossRefPubMed Colpi GM, Contalbi GF, Nerva F, et al. Testicular function following chemo-radiotherapy. Eur J Obstet Gynecol Reprod Biol. 2004;113 Suppl 1:S2–6.CrossRefPubMed
34.
go back to reference Shalet SM. Effect of irradiation treatment on gonadal function in men treated for germ cell cancer. Eur Urol. 1993;23:148–51.PubMed Shalet SM. Effect of irradiation treatment on gonadal function in men treated for germ cell cancer. Eur Urol. 1993;23:148–51.PubMed
35.
go back to reference Huyghe E, Matsuda T, Daudin M, et al. Fertility after testicular cancer treatments. Results of a large multicenter study. Cancer. 2004;100:732–7.CrossRefPubMed Huyghe E, Matsuda T, Daudin M, et al. Fertility after testicular cancer treatments. Results of a large multicenter study. Cancer. 2004;100:732–7.CrossRefPubMed
Metadata
Title
Fertility in patients treated for testicular cancer
Authors
Erika Matos
Breda Škrbinc
Branko Zakotnik
Publication date
01-09-2010
Publisher
Springer US
Published in
Journal of Cancer Survivorship / Issue 3/2010
Print ISSN: 1932-2259
Electronic ISSN: 1932-2267
DOI
https://doi.org/10.1007/s11764-010-0135-9

Other articles of this Issue 3/2010

Journal of Cancer Survivorship 3/2010 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine